Format

Send to

Choose Destination
Vet Comp Orthop Traumatol. 2017 Sep 12;30(5):318-323. doi: 10.3415/VCOT-17-02-0020. Epub 2017 Aug 1.

Efficacy of an oral nutraceutical for the treatment of canine osteoarthritis. A double-blind, randomized, placebo-controlled prospective clinical trial.

Author information

1
Ruth M. Scott, DVM, University of Minnesota, College of Veterinary Medicine, 1352 Boyd Ave., St. Paul, MN 55108, United States, Phone: + 1 612 626 8387, Fax: + 1 612 626 3569, E-mail: rmscott@umn.edu, Received: February 5, 2017, Accepted: April 19, 2017, Epub ahead of print: August 1, 2017.

Abstract

OBJECTIVES:

To assess the safety and efficacy of an orally administered nutraceutical (Glu/CS+; + for additional ingredient) for the treatment of clinical osteoarthritis (OA) in dogs.

METHODS:

In this double-blind, randomized, placebo-controlled clinical trial, client-owned dogs with clinical signs of OA in one or more joints were assigned to a Glu/CS+ (n = 30) or placebo (n = 30) group. Dogs were administered Glu/CS+ or placebo orally and wore an activity monitor (AM) continuously throughout a 97 day study period. Prior to the initiation of the treatment, seven days of baseline activity was collected. On days -7, 30, 60 and 90 of the study, owners completed a patient assessment form (Canine Brief Pain Inventory). Data between groups were compared.

RESULTS:

No serious adverse events were reported. No difference was found between groups when evaluating daily activity counts during the seven-day pre-treatment period and the 90-day treatment period. Owner assessment (pain interference and pain severity scores) improved over the 90-day treatment period for both groups, however no difference was found between treatment groups.

CONCLUSIONS:

Treatment with oral Glu/CS+ for a 90 day treatment period when compared to placebo treatment did not result in a significant increase in activity counts in dogs with clinical OA. However, owner assessment scores similarly improved throughout the study period for dogs in both groups, suggesting a caregiver placebo effect in this outcome measure.

KEYWORDS:

Dogs; activity monitor; chondroitin; glucosamine; osteoarthritis

PMID:
28763523
DOI:
10.3415/VCOT-17-02-0020
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center